Skip to main content

Table 3 Results of multivariate Cox regression analyses for clinicopathological factors and CXCL16 in stromal cells (model 1) and co-expression of CXCL16 in cancer and stromal cells (model 2*)

From: Erratum to: Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival

Factor HR CI 95% P
T-status    <0.001
 T1 1.00   
 T2 1.60 (0.97-2.64) 0.065
 T3 3.80 (2.13-6.77) <0.001
N-status    <0.001
 N0 1.00   
 N1 2.01 (1.30-3.11) 0.002
 N2 3.08 (1.74-5.44) <0.001
Differentiation    0.009
 Well 1.00   
 Moderate 1.17 (0.63-2.20) 0.618
 Poor 2.08 (1.12-3.85) 0.020
Performance status    0.040
 ECOG 0 1.00   
 ECOG 1 1.52 (1.02-2.26) 0.040
 ECOG 2 2.15 (0.94-4.91) 0.069
Vascular infiltration    
 No 1.00   
 Yes 1.70 (1.01-2.87) 0.046
Histology    <0.001
 Squamous carcinoma 1.00   
 Adenocarcinoma 2.23 (1.48-3.35) <0.001
 Large cell carcinoma 0.80 (0.39-1.66) 0.555
CXC16 stromal cells    
 Low 1   
 High 0.55 (0.35-0.87) 0.011
CXCL16 cancer and stromal cells*    0.031
 Low/Low 1.00   
 Low/High + High/Low 0.57 (0.35-0.93) 0.023
 High/High 0.42 (0.20-0.88) 0.022
  1. Overall significance as prognostic marker. HR, Hazard ratio. Bold values indicate p < 0.05